Published in Mol Cell Endocrinol on November 29, 2007
Clinical, quality of life, and economic value of acromegaly disease control. Pituitary (2011) 1.44
Acromegaly. Endocrinol Metab Clin North Am (2008) 1.23
Pituitary somatostatin receptor signaling. Trends Endocrinol Metab (2010) 1.03
The changing face of acromegaly--advances in diagnosis and treatment. Nat Rev Endocrinol (2012) 1.03
Inhibition of tumor promoting signals by activation of SSTR2 and opioid receptors in human breast cancer cells. Cancer Cell Int (2013) 0.86
The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly. Pituitary (2016) 0.83
Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly. Pituitary (2012) 0.82
Bright fluorescence monitoring system utilizing Zoanthus sp. green fluorescent protein (ZsGreen) for human G-protein-coupled receptor signaling in microbial yeast cells. PLoS One (2013) 0.77
Pasireotide: a novel treatment for patients with acromegaly. Drug Des Devel Ther (2016) 0.77
Alteration of somatostatin receptor 2 expression in canine mammary gland tumor. J Vet Med Sci (2015) 0.77
Pathophysiology of GPCR Homo- and Heterodimerization: Special Emphasis on Somatostatin Receptors. Pharmaceuticals (Basel) (2012) 0.76
Expression of Somatostatin Receptor 2 in Somatotropinoma Correlated with the Short-Term Efficacy of Somatostatin Analogues. Int J Endocrinol (2017) 0.75
Clinical utility of lanreotide Autogel(®) in gastroenteropancreatic neuroendocrine tumors. Drug Des Devel Ther (2016) 0.75
Somatostatin and its receptor family. Front Neuroendocrinol (1999) 3.69
Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev (2004) 3.14
Factors influencing mortality in acromegaly. J Clin Endocrinol Metab (2004) 2.69
Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov (2003) 2.11
Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group. J Clin Endocrinol Metab (1996) 1.96
Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab (2005) 1.58
Consensus statement: medical management of acromegaly. Eur J Endocrinol (2005) 1.54
First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group. J Endocrinol Invest (2006) 1.52
A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly. Eur J Endocrinol (1999) 1.43
Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) (1994) 1.40
Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab (2006) 1.35
Somatostatin analogs in acromegaly. J Clin Endocrinol Metab (2002) 1.33
Sandostatin LAR in acromegalic patients: long-term treatment. J Clin Endocrinol Metab (1997) 1.26
Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab (1997) 1.26
Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab (2002) 1.25
A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab (2005) 1.23
Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab (2002) 1.18
Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin Endocrinol (Oxf) (2000) 1.15
Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab (2003) 1.15
Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab (2001) 1.07
Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab (2006) 1.06
Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clin Endocrinol (Oxf) (2006) 1.05
Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group. Pituitary (1999) 1.04
Clinical endocrinology and metabolism. The somatostatin neuroendocrine system: physiology and clinical relevance in gastrointestinal and pancreatic disorders. Best Pract Res Clin Endocrinol Metab (2004) 1.03
Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly. J Clin Endocrinol Metab (2002) 1.00
Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients. Metabolism (1996) 0.99
Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial. Clin Endocrinol (Oxf) (2006) 0.98
Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). J Clin Endocrinol Metab (2000) 0.98
Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clin Endocrinol (Oxf) (1998) 0.97
Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf) (2002) 0.97
Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J Clin Endocrinol Metab (2007) 0.97
Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy. Clin Endocrinol (Oxf) (2004) 0.93
Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel). Exp Clin Endocrinol Diabetes (2005) 0.92
Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J Clin Endocrinol Metab (2000) 0.91
Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. Drugs (2003) 0.91
Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage. Clin Endocrinol (Oxf) (2003) 0.90
First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clin Endocrinol (Oxf) (2006) 0.90
Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clin Endocrinol (Oxf) (2003) 0.90
Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days. Clin Endocrinol (Oxf) (2005) 0.90
Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients. Clin Endocrinol (Oxf) (2006) 0.90
Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab (1995) 0.88
Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. J Clin Endocrinol Metab (2003) 0.88
Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. J Clin Endocrinol Metab (1994) 0.87
Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients. Eur J Endocrinol (2000) 0.87
Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel. Metabolism (2005) 0.86
Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution. Clin Endocrinol (Oxf) (2005) 0.86
Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients. J Clin Endocrinol Metab (1999) 0.83
Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. J Clin Endocrinol Metab (2005) 0.83
Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study. J Endocrinol Invest (2002) 0.82
Cardiovascular consequences of early-onset growth hormone excess. J Clin Endocrinol Metab (2002) 0.81
Combination of continuous subcutaneous infusion of insulin and octreotide in Type 1 diabetic patients. Diabetes Res Clin Pract (2001) 0.81
Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog). Am J Cardiol (1999) 0.81
Clinical review 154: The role of pharmacotherapy in perioperative management of patients with acromegaly. J Clin Endocrinol Metab (2003) 0.80
The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly. Clin Endocrinol (Oxf) (1996) 0.80
Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clin Endocrinol (Oxf) (2003) 0.80
A comparison of lanreotide and octreotide LAR for treatment of acromegaly. Clin Endocrinol (Oxf) (1999) 0.80
Effect of Sandostatin LAR on sleep apnoea in acromegaly: correlation with computerized tomographic cephalometry and hormonal activity. Clin Endocrinol (Oxf) (2001) 0.79
Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide. Eur J Endocrinol (1994) 0.78
Effects of two different somatostatin analogs on glucose tolerance in acromegaly. J Endocrinol Invest (2002) 0.77
Effects of treatment with Sandostatin LAR on small dense LDL and remnant-like lipoproteins in patients with acromegaly. Clin Endocrinol (Oxf) (2003) 0.77
Current pharmacotherapy for acromegaly: a review. Expert Opin Pharmacother (2005) 0.77
Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201-995). Ann Intern Med (1986) 0.77
Efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in the treatment of acromegaly. Metabolism (2002) 0.77
Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab (2012) 2.87
Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2014) 2.01
Elucidating the murine brain transcriptional network in a segregating mouse population to identify core functional modules for obesity and diabetes. J Neurochem (2006) 2.00
Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocr Rev (2007) 1.79
Angiogenesis in endocrine tumors. Endocr Rev (2003) 1.50
EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J Clin Invest (2011) 1.49
Pituitary hypoplasia in Pttg-/- mice is protective for Rb+/- pituitary tumorigenesis. Mol Endocrinol (2005) 1.40
Pituitary magnetic resonance imaging for sellar and parasellar masses: ten-year experience in 2598 patients. J Clin Endocrinol Metab (2011) 1.34
p21(Cip1) restrains pituitary tumor growth. Proc Natl Acad Sci U S A (2008) 1.31
Overexpressed pituitary tumor-transforming gene causes aneuploidy in live human cells. Endocrinology (2003) 1.29
Functional role of estrogen in pituitary tumor pathogenesis. J Clin Invest (2002) 1.24
Acromegaly. Endocrinol Metab Clin North Am (2008) 1.23
A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab (2008) 1.19
Pituitary tumor transforming gene-null male mice exhibit impaired pancreatic beta cell proliferation and diabetes. Proc Natl Acad Sci U S A (2003) 1.19
PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. J Clin Invest (2003) 1.18
Early multipotential pituitary focal hyperplasia in the alpha-subunit of glycoprotein hormone-driven pituitary tumor-transforming gene transgenic mice. Mol Endocrinol (2005) 1.18
Body mass index determines evoked growth hormone (GH) responsiveness in normal healthy male subjects: diagnostic caveat for adult GH deficiency. J Clin Endocrinol Metab (2004) 1.15
Molecular targets in pituitary tumours. Nat Rev Cancer (2004) 1.14
The neuroprotective WldS gene regulates expression of PTTG1 and erythroid differentiation regulator 1-like gene in mice and human cells. Hum Mol Genet (2006) 1.14
Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med (2002) 1.14
Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth. Cancer Res (2007) 1.09
Pituitary corticotroph ontogeny and regulation in transgenic zebrafish. Mol Endocrinol (2003) 1.09
Single-surgeon fully endoscopic endonasal transsphenoidal surgery: outcomes in three-hundred consecutive cases. Pituitary (2013) 1.08
The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab (2008) 1.08
Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. J Clin Invest (2004) 1.06
Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor. Proc Natl Acad Sci U S A (2011) 1.05
Ectopic acromegaly due to growth hormone releasing hormone. Endocrine (2012) 1.05
Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS One (2012) 1.05
Minireview: Neuro-immuno-endocrine modulation of the hypothalamic-pituitary-adrenal (HPA) axis by gp130 signaling molecules. Endocrinology (2002) 1.04
Lipodystrophy in patients with acromegaly receiving pegvisomant. J Clin Endocrinol Metab (2008) 1.03
Pituitary somatostatin receptor signaling. Trends Endocrinol Metab (2010) 1.03
Pituitary tumor transforming gene overexpression facilitates pituitary tumor development. Endocrinology (2006) 1.02
Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands. Cancer Res (2008) 0.98
Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J Clin Endocrinol Metab (2014) 0.96
Lineage-specific restraint of pituitary gonadotroph cell adenoma growth. PLoS One (2011) 0.95
A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axis. J Clin Invest (2012) 0.94
Growth hormone is a cellular senescence target in pituitary and nonpituitary cells. Proc Natl Acad Sci U S A (2013) 0.93
Zebrafish usp39 mutation leads to rb1 mRNA splicing defect and pituitary lineage expansion. PLoS Genet (2011) 0.92
Acromegaly with moderate hyperprolactinemia caused by an intrasellar macroadenoma. Nat Clin Pract Endocrinol Metab (2006) 0.90
Ovarian hyperstimulation syndrome caused by an FSH-secreting pituitary adenoma. Nat Clin Pract Endocrinol Metab (2008) 0.90
HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy. Mol Endocrinol (2010) 0.90
Regulation of growth hormone and prolactin gene expression and secretion by chimeric somatostatin-dopamine molecules. Endocrinology (2007) 0.89
Prolactin receptor signaling mediates the osmotic response of embryonic zebrafish lactotrophs. Mol Endocrinol (2005) 0.89
Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. J Clin Endocrinol Metab (2003) 0.89
Aryl hydrocarbon receptor interacting protein variants in sporadic pituitary adenomas. J Clin Endocrinol Metab (2006) 0.89
Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes. Horm Cancer (2010) 0.88
Subclinical hyperfunctioning pituitary adenomas: the silent tumors. Best Pract Res Clin Endocrinol Metab (2012) 0.88
Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study. Pituitary (2014) 0.87
Heregulin regulates prolactinoma gene expression. Cancer Res (2009) 0.87
Changing patterns of the adult growth hormone deficiency diagnosis documented in a decade-long global surveillance database. J Clin Endocrinol Metab (2008) 0.87
Constitutive somatostatin receptor activity determines tonic pituitary cell response. Mol Endocrinol (2009) 0.86
Treatment of acromegaly: future. Endocrine (2005) 0.86
The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. J Clin Endocrinol Metab (2004) 0.86
Prospective safety surveillance of GH-deficient adults: comparison of GH-treated vs untreated patients. J Clin Endocrinol Metab (2013) 0.86
Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion. J Clin Endocrinol Metab (2003) 0.86
Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activation. Mol Endocrinol (2007) 0.85
Metabolic, cardiovascular, and cerebrovascular outcomes in growth hormone-deficient subjects with previous cushing's disease or non-functioning pituitary adenoma. J Clin Endocrinol Metab (2009) 0.85
The cell adhesion molecules N-cadherin and neural cell adhesion molecule regulate human growth hormone: a novel mechanism for regulating pituitary hormone secretion. J Clin Endocrinol Metab (2003) 0.84
Expression and function of ErbB receptors and ligands in the pituitary. Endocr Relat Cancer (2011) 0.84
E2F1 induces pituitary tumor transforming gene (PTTG1) expression in human pituitary tumors. Mol Endocrinol (2009) 0.84
Pituitary tumor transforming gene: an update. Front Horm Res (2004) 0.84
Sca1⁺ murine pituitary adenoma cells show tumor-growth advantage. Endocr Relat Cancer (2014) 0.83
Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion. J Biol Chem (2005) 0.83
Pasireotide--a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease. IDrugs (2007) 0.83
Skin manifestations in acromegaly. Clin Dermatol (2006) 0.83
Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy. J Clin Endocrinol Metab (2009) 0.83
Supplemental growth hormone in healthy adults: the endocrinologist's responsibility. Nat Clin Pract Endocrinol Metab (2006) 0.83
Discordant proliferation and differentiation in pituitary tumor-transforming gene-null bone marrow stem cells. Am J Physiol Cell Physiol (2007) 0.83
Human pituitary tumor-transforming gene (PTTG1) motif suppresses prolactin expression. Mol Endocrinol (2003) 0.82
A structural and functional acromegaly classification. J Clin Endocrinol Metab (2015) 0.82
Pituitary senescence: the evolving role of Pttg. Mol Cell Endocrinol (2010) 0.82
PTTG1 attenuates drug-induced cellular senescence. PLoS One (2011) 0.82
Cell-specific pituitary gene expression profiles after treatment with leukemia inhibitory factor reveal novel modulators for proopiomelanocortin expression. Endocrinology (2003) 0.82
Pituitary tumour-transforming gene (PTTG) and pituitary senescence. Horm Res (2009) 0.82
Clusterin and FOXL2 act concordantly to regulate pituitary gonadotroph adenoma growth. Mol Endocrinol (2012) 0.81
STAT3 upregulation in pituitary somatotroph adenomas induces growth hormone hypersecretion. J Clin Invest (2015) 0.81
Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand. J Clin Endocrinol Metab (2003) 0.81
Oct-1 induces pituitary tumor transforming gene expression in endocrine tumors. Endocr Relat Cancer (2008) 0.80
Patient guide to hyperprolactinemia diagnosis and treatment. J Clin Endocrinol Metab (2011) 0.80
Constitutive somatostatin receptor subtype-3 signaling suppresses growth hormone synthesis. Mol Endocrinol (2014) 0.80
In vivo time-lapse imaging delineates the zebrafish pituitary proopiomelanocortin lineage boundary regulated by FGF3 signal. Dev Biol (2008) 0.80
Pituitary adenoma growth: a model for cellular senescence and cytokine action. Cell Cycle (2009) 0.80
ErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic mice. Endocrinology (2015) 0.80
Acromegaly consensus: the next steps. J Clin Endocrinol Metab (2003) 0.80
Clinical review 154: The role of pharmacotherapy in perioperative management of patients with acromegaly. J Clin Endocrinol Metab (2003) 0.80
Somatostatin analogs and chimeric somatostatin-dopamine molecules differentially regulate human growth hormone and prolactin gene expression and secretion in vitro. Mol Cell Endocrinol (2012) 0.79
The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome. Pituitary (2010) 0.79
CEBPD suppresses prolactin expression and prolactinoma cell proliferation. Mol Endocrinol (2011) 0.79
Constitutive activity of somatostatin receptor subtypes. Methods Enzymol (2010) 0.79
Genomic characterization of human and rat prolactinomas. Endocrinology (2012) 0.79
Molecular mechanisms of pituitary adenoma senescence. Front Horm Res (2010) 0.78
Elevated circulating leukemia inhibitory factor in patients with extensive burns. J Burn Care Res (2006) 0.78
Anti-aging therapy with human growth hormone associated with metastatic colon cancer in a patient with Crohn's colitis. Clin Gastroenterol Hepatol (2008) 0.78
Murine pituitary tumor-transforming gene functions as a securin protein in insulin-secreting cells. J Endocrinol (2006) 0.78
Pathogenesis of pituitary tumors. Prog Brain Res (2010) 0.78
Pyridoxal phosphate inhibits pituitary cell proliferation and hormone secretion. Endocrinology (2006) 0.77
Fibroblast growth factor-2 autofeedback regulation in pituitary folliculostellate TtT/GF cells. Endocrinology (2009) 0.77
Estradiol partially recapitulates murine pituitary cell cycle response to pregnancy. Endocrinology (2012) 0.76
2004 World Health Organization classification of pituitary tumors: what is new? Acta Neuropathol (2005) 0.76